Podrobný výpis o publikaci

BOWER, M., T. METZGER, K. ROBBINS, D. TOMALTY, Vlastimil VÁLEK, Jaroslav BOUDNÝ, Tomáš ANDRAŠINA, C. TATUM a RC. MARTIN. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford). 2010, roč. 12,2010, č. 1, s. 31-36, 5 s. ISSN 1365-182X. Dostupné z: https://dx.doi.org/10.1111/j.1477-2574.2009.00117.x.

Další formáty: BibTeX LaTeX RIS

TY  - JOUR
ID  - 896289
AU  - Bower, M. - Metzger, T. - Robbins, K. - Tomalty, D. - Válek, Vlastimil - Boudný, Jaroslav - Andrašina, Tomáš - Tatum, C. - Martin, RC.
PY  - 2010
TI  - Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study
JF  - HPB (Oxford)
VL  - 12,2010
IS  - 1
SP  - 31-36
EP  - 31-36
SN  - 1365182X
KW  - metastatic colon cancer
KW  - liver directed therapy
KW  - chemoembolization
KW  - irinotecan
N2  - Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC) is becoming a more common treatment algorithm. The aim of the present study was to evaluate the efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC. Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection. Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between 26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number of hepatic lesions was four (range 1-20), with a median total size of all target lesions of 9 cm (range 5.5-28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan treatments was two (range 1-5). The median treatment dose was 100 mg (range 100-200) with a median total hepatic treatment of 200 mg (range 200-650). The majority of treatments (86%) were performed as lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy. Eleven (20%) patients demonstrated significant response and downstage of their disease or demonstrated stable disease without extra-hepatic disease progression allowing resection, ablation or resection and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in 18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no evidence of steatohepatitis from the irinotecan arterial infusion. Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned hepatic resection.
ER  -

Základní údaje
Originální název	Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study
Autoři	BOWER, M. (840 Spojené státy), T. METZGER (840 Spojené státy), K. ROBBINS (840 Spojené státy), D. TOMALTY (840 Spojené státy), Vlastimil VÁLEK (203 Česká republika, domácí), Jaroslav BOUDNÝ (203 Česká republika), Tomáš ANDRAŠINA (703 Slovensko, domácí), C. TATUM (840 Spojené státy) a RC. MARTIN (840 Spojené státy, garant).
Vydání	HPB (Oxford), 2010, 1365-182X.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	30200 3.2 Clinical medicine
Stát vydavatele	Spojené státy
Utajení	není předmětem státního či obchodního tajemství
Impakt faktor	Impact factor: 1.285
Kód RIV	RIV/00216224:14110/10:00051437
Organizační jednotka	Lékařská fakulta
Doi	http://dx.doi.org/10.1111/j.1477-2574.2009.00117.x
UT WoS	000286434900005
Klíčová slova anglicky	metastatic colon cancer; liver directed therapy; chemoembolization; irinotecan
Změnil	Změnil: MUDr. Tomáš Andrašina, Ph.D., učo 51232. Změněno: 11. 1. 2012 20:49.

Anotace
Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC) is becoming a more common treatment algorithm. The aim of the present study was to evaluate the efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC. Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection. Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between 26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number of hepatic lesions was four (range 1-20), with a median total size of all target lesions of 9 cm (range 5.5-28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan treatments was two (range 1-5). The median treatment dose was 100 mg (range 100-200) with a median total hepatic treatment of 200 mg (range 200-650). The majority of treatments (86%) were performed as lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy. Eleven (20%) patients demonstrated significant response and downstage of their disease or demonstrated stable disease without extra-hepatic disease progression allowing resection, ablation or resection and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in 18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no evidence of steatohepatitis from the irinotecan arterial infusion. Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned hepatic resection.

Anotace

Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC) is becoming a more common treatment algorithm. The aim of the present study was to evaluate the efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC. Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection. Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between 26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number of hepatic lesions was four (range 1-20), with a median total size of all target lesions of 9 cm (range 5.5-28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan treatments was two (range 1-5). The median treatment dose was 100 mg (range 100-200) with a median total hepatic treatment of 200 mg (range 200-650). The majority of treatments (86%) were performed as lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy. Eleven (20%) patients demonstrated significant response and downstage of their disease or demonstrated stable disease without extra-hepatic disease progression allowing resection, ablation or resection and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in 18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no evidence of steatohepatitis from the irinotecan arterial infusion. Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned hepatic resection.